Paper19854499
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.
Maguire AM and 32 others. Lancet, 2009. Cited by 694 papers, by iCite.
Cite this record
ConductScience Library. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Papers, record 19854499. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19854499
- Disease
- Leber congenital amaurosis6 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics27
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carrier Proteins | Major topic |
| Eye Proteins | Major topic |
| Genetic Therapy | Major topic |
| Optic Atrophy, Hereditary, Leber | Major topic |
| Adolescent | |
| Adult | |
| Age Factors | |
| Blindness | |
| Child | |
| Dark Adaptation | |
| Dependovirus | |
| Disease Progression | |
| Dose-Response Relationship, Drug | |
| Electroretinography | |
| Female | |
| Genetic Vectors | |
| Humans | |
| Injections | |
| Male | |
| Mutation | |
| Nystagmus, Physiologic | |
| Safety | |
| Treatment Outcome | |
| Visual Acuity | |
| Young Adult | |
| cis-trans-Isomerases | |
| Retinoid Isomerohydrolase |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Howard Hughes Medical Institute | United States | PubMed | PubMed | ||
| GGP07180 | Telethon | Italy | PubMed | PubMed | |
| U10 EY013729 | NEI NIH HHS | United States | U10EY013729 | PubMed and NIH | NIH RePORTER |
| UL1-RR-024134 | NCRR NIH HHS | United States | UL1RR024134 | PubMed and NIH | NIH RePORTER |
| R01 EY010820 | NEI NIH HHS | United States | R01EY010820 | PubMed and NIH | NIH RePORTER |
| TGM06B01 | Telethon | Italy | PubMed | PubMed | |
| UL1 RR024134 | NCRR NIH HHS | United States | UL1RR024134 | PubMed and NIH | NIH RePORTER |
| ZIAEY000260 | NIH | NIH RePORTER |
Trials3
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT00516477 | Safety Study in Subjects With Leber Congenital Amaurosis | Results | Yes | ClinicalTrials.gov |
| NCT00999609 | Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis | Background | ClinicalTrials.gov | |
| NCT01208389 | Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 | Background | ClinicalTrials.gov |
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 19854500 | Promises and challenges of genetic therapy for blindness. | https://conductscience.org/library/papers/19854500 |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15037595 | Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. | Invest Ophthalmol Vis Sci | 2004 | https://conductscience.org/library/papers/15037595 | PubMed |
| 2 | 15957611 | Test-retest reliability of the multifocal electroretinogram and humphrey visual fields in patients with retinitis pigmentosa. | Doc Ophthalmol | 2004 | https://conductscience.org/library/papers/15957611 | PubMed |
| 3 | 19583479 | Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. | Hum Gene Ther | 2009 | https://conductscience.org/library/papers/19583479 | PubMed |
| 4 | 18774912 | Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. | Hum Gene Ther | 2008 | https://conductscience.org/library/papers/18774912 | PubMed |
| 5 | 18809924 | Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18809924 | PubMed |
| 6 | 16096063 | Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium. | Cell | 2005 | https://conductscience.org/library/papers/16096063 | PubMed |
| 7 | 19675341 | Vision 1 year after gene therapy for Leber's congenital amaurosis. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19675341 | PubMed |
| 8 | 18441370 | Safety and efficacy of gene transfer for Leber's congenital amaurosis. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18441370 | PubMed |
| 9 | 14759802 | In utero gene therapy rescues vision in a murine model of congenital blindness. | Mol Ther | 2004 | https://conductscience.org/library/papers/14759802 | PubMed |
| 10 | 16226919 | Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. | Mol Ther | 2005 | https://conductscience.org/library/papers/16226919 | PubMed |
| 11 | 10937591 | Early-onset severe rod-cone dystrophy in young children with RPE65 mutations. | Invest Ophthalmol Vis Sci | 2000 | https://conductscience.org/library/papers/10937591 | PubMed |
| 12 | 16799026 | Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. | Invest Ophthalmol Vis Sci | 2006 | https://conductscience.org/library/papers/16799026 | PubMed |
| 13 | 16150724 | Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/16150724 | PubMed |
| 14 | 9843205 | Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. | Nat Genet | 1998 | https://conductscience.org/library/papers/9843205 | PubMed |
| 15 | 17724218 | Clinical and molecular genetics of Leber's congenital amaurosis: a multicenter study of Italian patients. | Invest Ophthalmol Vis Sci | 2007 | https://conductscience.org/library/papers/17724218 | PubMed |
| 16 | 18209734 | Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. | Mol Ther | 2008 | https://conductscience.org/library/papers/18209734 | PubMed |
| 17 | 19953081 | Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. | Mol Ther | 2010 | https://conductscience.org/library/papers/19953081 | PubMed |
| 18 | 3976802 | Natural course of retinitis pigmentosa over a three-year interval. | Am J Ophthalmol | 1985 | https://conductscience.org/library/papers/3976802 | PubMed |
| 19 | 8382952 | Amplification and kinetics of the activation steps in phototransduction. | Biochim Biophys Acta | 1993 | https://conductscience.org/library/papers/8382952 | PubMed |
| 20 | 12657591 | Latency of the pupil light reflex: sample rate, stimulus intensity, and variation in normal subjects. | Invest Ophthalmol Vis Sci | 2003 | https://conductscience.org/library/papers/12657591 | PubMed |
Cited by464
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 694 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42817933 | Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular Toxicity. | bioRxiv | 2026 | https://conductscience.org/library/papers/42817933 | PubMed |
| 42488178 | mRNA delivery to the retina restores REP1 function in choroideremia. | Mol Ther Adv | 2026 | https://conductscience.org/library/papers/42488178 | PubMed |
| 42242173 | Vein graft failure: Pathophysiology, detection, prevention and emerging therapeutic strategies. | Pharmacol Rev | 2026 | https://conductscience.org/library/papers/42242173 | PubMed |
| 42117798 | Voretigene Neparvovec Gene Therapy in Clinical Practice: A 12-Month, Single-Center, In-Depth Analysis of Beneficial and Adverse Drug Effects. | Transl Vis Sci Technol | 2026 | https://conductscience.org/library/papers/42117798 | PubMed |
| 42107518 | Modalities of vision restoration in optic neuropathies and retinal disease. | Prog Retin Eye Res | 2026 | https://conductscience.org/library/papers/42107518 | PubMed |
| 42083640 | Gene Therapy Using Recombinant Adeno-Associated Virus for Leber Congenital Amaurosis Induced by RPE65 Mutation. | Clin Ophthalmol | 2026 | https://conductscience.org/library/papers/42083640 | PubMed |
| 41751276 | Diagnostic Role of Chromatic Full-Field Stimulus Test in Rod-Cone Versus Cone Dystrophies. | Biomedicines | 2026 | https://conductscience.org/library/papers/41751276 | PubMed |
| 41618563 | Modification of the VP1u region boosts transduction of adeno-associated virus vectors for ocular gene therapy. | Mol Ther | 2026 | https://conductscience.org/library/papers/41618563 | PubMed |
| 41512965 | RNA-Based Therapies for Treating Monogenic Cardiomyopathies. | Can J Cardiol | 2026 | https://conductscience.org/library/papers/41512965 | PubMed |
| 41379738 | Chorioretinal Atrophy after Voretigene Neparvovec Therapy in <italic>RPE65</italic> Mutation-Associated Inherited Retinal Disease: Longitudinal Characterization in Multimodal Imaging. | Ophthalmologica | 2026 | https://conductscience.org/library/papers/41379738 | PubMed |
| 41254285 | Roadmap for direct and indirect translation of optogenetics into discoveries and therapies for humans. | Nat Neurosci | 2025 | https://conductscience.org/library/papers/41254285 | PubMed |
| 41223291 | Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2. | Sci Adv | 2025 | https://conductscience.org/library/papers/41223291 | PubMed |
| 41141388 | In vivo gene therapy: A strategy for mutations, degenerations, and tumors. | Genes Dis | 2026 | https://conductscience.org/library/papers/41141388 | PubMed |
| 41140124 | Clinical and pharmacovigilance safety evaluation of LUXTURNA® (voretigene neparvovec-rzyl). | Cutan Ocul Toxicol | 2025 | https://conductscience.org/library/papers/41140124 | PubMed |
| 41104263 | Characterization of adeno-associated viral transduction of retinal ganglion cells in adult and old mice. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/41104263 | PubMed |
| 40910102 | Efficacy and Safety of Voretigene Neparvovec in RPE65-Retinopathy: Results of a Phase III Trial in Japan. | Ophthalmol Sci | 2025 | https://conductscience.org/library/papers/40910102 | PubMed |
| 40725503 | Advances in Precision Therapeutics and Gene Therapy Applications for Retinal Diseases: Impact and Future Directions. | Genes (Basel) | 2025 | https://conductscience.org/library/papers/40725503 | PubMed |
| 40715346 | Regulation of RPE65 expression in human retinal pigment epithelium cells. | Sci Rep | 2025 | https://conductscience.org/library/papers/40715346 | PubMed |
| 40471435 | Gene therapy strategies in ophthalmology-an overview of current developments and future prospects. | J Appl Genet | 2026 | https://conductscience.org/library/papers/40471435 | PubMed |
| 40248125 | The clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis. | iScience | 2025 | https://conductscience.org/library/papers/40248125 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DCC | 1630 | PubTator's text mining | https://conductscience.org/library/genes/1630 | NCBI Gene |
| IFI27 | 3429 | PubTator's text mining | https://conductscience.org/library/genes/3429 | NCBI Gene |
| NDUFB11 | 54539 | PubTator's text mining | https://conductscience.org/library/genes/54539 | NCBI Gene |
| POTEF | 728378 | PubTator's text mining | https://conductscience.org/library/genes/728378 | NCBI Gene |
| RDH12 | 145226 | PubTator's text mining | https://conductscience.org/library/genes/145226 | NCBI Gene |
| RPE65 | 6121 | PubTator's text mining | https://conductscience.org/library/genes/6121 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| VORETIGENE NEPARVOVEC | CHEMBL3707275 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL3707275 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19854499
GET https://conductscience.org/api/papers/v1/19854499/authors?page=2